Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

ALAMEDA, Calif.--(BUSINESS WIRE)--Nov 27, 2024--

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December:

• Piper Sandler 36 th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City.
• Citi 2024 Global Healthcare Conference: Exelixis is scheduled to present at 1:45 p.m. ET / 10:45 a.m. PT on Wednesday, December 4 in Miami.

To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241126763789/en/

CONTACT: Investors Contact:

Varant Shirvanian

Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.comMedia Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

KEYWORD: CALIFORNIA NEW YORK FLORIDA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Exelixis, Inc.

Copyright Business Wire 2024.